CRL - CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

QQQ $ 445.88 $ 2.85 (0.64 %)

DIA $ 395.58 $ 1.12 (0.28 %)

SPY $ 523.16 $ 2.39 (0.46 %)

TLT $ 90.86 $ 0.51 (0.56 %)

GLD $ 218.12 $ 1.83 (0.85 %)

Previous Close

$ 232.82

Open

$ 230.08

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 229.94 - $ 233.15

52 Week Range

$ 161.65 - $ 275.00

Volume

502,307

Average Volume

Market Cap

12.07B

Beta (5Y Monthly)

$ 1.34

PE Ratio (TTM)

$ 27.16

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-30-2024	10-Q
2	02-14-2024	12-30-2023	10-K
3	11-08-2023	09-30-2023	10-Q
4	08-09-2023	07-01-2023	10-Q
5	05-11-2023	04-01-2023	10-Q
6	02-22-2023	12-31-2022	10-K
7	11-02-2022	09-24-2022	10-Q
8	08-03-2022	06-25-2022	10-Q
9	05-04-2022	03-26-2022	10-Q
10	02-16-2022	12-25-2021	10-K
11	11-03-2021	09-25-2021	10-Q
12	08-04-2021	06-26-2021	10-Q
13	05-04-2021	03-27-2021	10-Q
14	02-17-2021	12-26-2020	10-K
15	11-09-2020	09-26-2020	10-Q
16	10-29-2020	09-26-2020	10-Q
17	08-05-2020	06-27-2020	10-Q
18	05-07-2020	03-28-2020	10-Q
19	02-11-2020	12-28-2019	10-K
20	11-06-2019	09-28-2019	10-Q
21	07-31-2019	06-29-2019	10-Q
22	05-07-2019	03-30-2019	10-Q
23	02-13-2019	12-29-2018	10-K
24	11-07-2018	09-29-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	02-13-2018	12-30-2017	10-K
28	11-09-2017	09-30-2017	10-Q
29	08-09-2017	07-01-2017	10-Q
30	05-10-2017	04-01-2017	10-Q
31	02-14-2017	12-31-2016	10-K
32	11-02-2016	09-24-2016	10-Q
33	08-03-2016	06-25-2016	10-Q
34	05-04-2016	03-26-2016	10-Q
35	02-12-2016	12-26-2015	10-K
36	11-04-2015	09-26-2015	10-Q
37	07-30-2015	06-27-2015	10-Q
38	04-30-2015	03-28-2015	10-Q
39	02-17-2015	12-27-2014	10-K
40	10-30-2014	09-27-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

TD Cowen Maintains Hold on Charles River, ...
05/13/2024 16:18:45

TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Hold and lowers the price target from $260 to $228.

The Analyst Landscape: 7 Takes On Charles ...
05/10/2024 12:00:43

Baird Maintains Outperform on Charles Rive...
05/10/2024 11:21:34

Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $282 to $270.

Charles River Laboratories Reaffirms Outlo...
05/09/2024 11:11:24

Despite modest adjustments to the quarterly gating in 2024, the Company's outlook for the year remains essentially unchang...

Charles River Q1 2024 Adj EPS $2.27 Beats ...
05/09/2024 11:02:38

Charles River (NYSE:CRL) reported quarterly earnings of $2.27 per share which beat the analyst consensus estimate of $2.07 by 9...

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
05/07/2024 17:35:23

Charles River Launches Viral Vector Refere...
05/02/2024 12:14:25

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developersCharles Ri...

FibroBiologics, Charles River Laboratories...
04/25/2024 12:02:58

This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of Fib...

Charles River Laboratories Launches Altern...
04/16/2024 12:04:39

Charles River To Perform Plasmid Productio...
04/04/2024 12:09:49

GMP grade plasmid DNA to serve as a direct therapeutic targeting various indicationsCharles River Laboratories International, I...

Charles River Announces Extension Of Gene ...
03/21/2024 12:04:57

Evaluating Charles River: Insights From 7 ...
03/18/2024 18:01:03

Argus Research Maintains Buy on Charles Ri...
03/18/2024 14:12:20

Argus Research analyst David Toung maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $200 to $290.

Charles River And Navega Therapeutics Anno...
03/14/2024 12:17:22

Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE:CR...

Durect Corporation Has Entered Into A Co-m...
03/04/2024 12:02:35

Wheeler Bio Taps Charles River to Offer Po...
02/29/2024 07:28:01

Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreeme...

Charles River And Wheeler Bio Complete Agr...
02/21/2024 13:28:08

Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic agreement with Wheeler Bio, Inc., an ant...

Charles River Collaborates With Pluristyx,...
02/20/2024 13:45:43

The addition of ES cells and iPSCs will enhance Charles River's portfolio of powerful research tools supporting acceleratio...

Forecasting The Future: 4 Analyst Projecti...
02/15/2024 16:01:13

Guggenheim Downgrades Charles River to Neu...
02/15/2024 13:02:47

Guggenheim analyst Sandy Draper downgrades Charles River (NYSE:CRL) from Buy to Neutral.